Reduction of chemotherapy and PET-guided radiotherapy in advanced-stage Hodgkin lymphoma: the GHSG HD15 trial

Using the multi-agent chemotherapy regimen BEACOPP the GHSG demonstrated significantly better tumor control and overall survival compared to previously used regimens. In addition, the need for radiotherapy in patients with advanced stage Hodgkin lymphoma has been unclear.

EMA Issues Call for Expressions of Interest for Drug Safety Studies

The purpose of this call is to enable the EMA to obtain fast and reliable answers to questions on safety or benefit/risk concerns, and ultimately facilitating regulatory decision-making.

Would you sell Peripheral Blood derived Stem Cells?

There are many things that are different in the United States of America (USA) and Europe. Some of these differences are in favour of society in the USA and some in Europe.

EHA supports the European Medicines Agency's investigation into risk based quality management of clinical trials

EHA has responded to the EMA’s call for comments on the reflection paper on February 15.

Horizon 2020: The European Commission proposes the successor to Framework Programme 7

Horizons 2020 will pay “particular attention to ensuring a broad approach to innovation, which is not only limited to the development of new products and services on the basis of scientific and technological breakthroughs, but which also incorporates aspects such…

New at EHA 15: EHA-JSH Joint Symposium

On behalf of JSH Dr Toshiki Watanabe will speak about "Molecular pathogenesis of ATL". Dr Herman Einsele presents EHA with his lecture "New treatments strategies for EBV-associated LPD as a model for immunotherapy of virus-associated/induced tumors".

Application forms redirect

Application forms redirect

Application forms redirect